NVS Novartis AG : Bullish and Bearish Analyst Opinions

BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.

Novartis agreed to acquire biotech firm Excelergy for up to $2 billion to strengthen its immunology and cancer drug portfolios. Acquisition enhances Novartis's growth prospects and diversifies its product pipeline, which is positive for future earnings and market position. LONG due to strategic expansion and positive market reaction, with shares outperforming peers year-to-date. Integration challenges or pipeline failures could undermine expected benefits.

Cramer notes that February "demolished software" and "minimized hardware" but the winners were "prosaic companies with popular brands" and "earthmovers." In a month of indecision, inflation, and rate fears, capital is fleeing high-beta tech and hiding in tangible, defensive value stocks and industrials. LONG. These are the current safe havens in a volatile market. A sudden return to "risk-on" sentiment could see these lag behind tech.

February winners were "prosaic companies" with popular brands and earth movers. In a month where software and hardware were demolished, capital hid in these defensive names. This trend is the current market regime. Winners/Holds. Rotation back into risk-on tech.